{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:29:43Z","timestamp":1793964583602,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":216,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clinsp.2026.101077","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:32:14Z","timestamp":1786465934000},"page":"101077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacokinetic and bioequivalence evaluation of two abiraterone acetate tablets under fasting conditions in healthy Chinese volunteers"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1705-9925","authenticated-orcid":false,"given":"Jinjin","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4024-9221","authenticated-orcid":false,"given":"Xiaoshan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7242-3028","authenticated-orcid":false,"given":"Xu","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1689-5055","authenticated-orcid":false,"given":"Ancheng","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2830-1844","authenticated-orcid":false,"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1674-6491","authenticated-orcid":false,"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-8688","authenticated-orcid":false,"given":"Guiying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7933-2837","authenticated-orcid":false,"given":"Tiandong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clinsp.2026.101077_bib0001","first-page":"688","article-title":"The incidence of prostate cancer and associated factors","volume":"12","author":"Li","year":"2003","journal-title":"China Cancer"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101077_bib0002","first-page":"55","article-title":"Interpretation of the updated version (2023.V4) of the NCCN Clinical Practice Guidelines: prostate cancer","volume":"32","author":"Yang","year":"2024","journal-title":"J Clin Surg"},{"issue":"12","key":"10.1016\/j.clinsp.2026.101077_bib0003","first-page":"89","article-title":"Diagnostic value of multi-parametric Magnetic resonance imaging and dynamic contrast-enhanced scanning in prostate cancer","volume":"8","author":"Wang","year":"2024","journal-title":"Imag Res Med Appl"},{"issue":"5","key":"10.1016\/j.clinsp.2026.101077_bib0004","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.seminoncol.2018.01.003","article-title":"The Surgical management of prostate cancer","volume":"44","author":"Sebesta","year":"2017","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.clinsp.2026.101077_bib0005","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.semnuclmed.2016.07.002","article-title":"Diagnostic and therapeutic strategies for prostate cancer","volume":"46","author":"Nguyen-Nielsen","year":"2016","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1016\/j.clinsp.2026.101077_bib0006","first-page":"231","article-title":"[Locally advanced prostate cancer. Definition, diagnosis and treatment.]","volume":"71","author":"Mayor de Castro","year":"2018","journal-title":"Arch Esp Urol"},{"issue":"3","key":"10.1016\/j.clinsp.2026.101077_bib0007","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/CCO.0000000000000624","article-title":"Recent progress in treating advanced prostate cancer","volume":"32","author":"Gourdin","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clinsp.2026.101077_bib0008","series-title":"[thesis]","article-title":"The effect of TC2N on the proliferation, invasion and migration of prostate cancer via the STAT3 pathway","author":"Qin","year":"2023"},{"issue":"17","key":"10.1016\/j.clinsp.2026.101077_bib0009","first-page":"1998","article-title":"A new drug for castration-resistant prostate cancer: abiraterone acetate","author":"Zhou","year":"2013","journal-title":"Chin J New Drugs"},{"issue":"03","key":"10.1016\/j.clinsp.2026.101077_bib0010","first-page":"118","article-title":"Research and development progress of abiraterone acetate","author":"He","year":"2014","journal-title":"World Biotechnol"},{"key":"10.1016\/j.clinsp.2026.101077_bib0011","series-title":"Abiraterone Acetate Tablets, Updated","year":"2025"},{"key":"10.1016\/j.clinsp.2026.101077_bib0012","series-title":"Catalogue of Reference Preparations for Generic Drugs (Batch 8)","year":"2017"},{"key":"10.1016\/j.clinsp.2026.101077_bib0013","series-title":"Technical Guidelines for Bioequivalence Studies of Abiraterone Acetate Tablets","year":"2021"},{"key":"10.1016\/j.clinsp.2026.101077_bib0014","first-page":"1989","article-title":"Pharmacokinetics and bioequivalence study of abiraterone acetate tablets in healthy Chinese subjects","volume":"34","author":"Wang","year":"2018","journal-title":"Chin J Clin Pharmacol"},{"key":"10.1016\/j.clinsp.2026.101077_bib0015","series-title":"Draft Guidance on Abiraterone Acetate","year":"2018"},{"key":"10.1016\/j.clinsp.2026.101077_bib0016","series-title":"Guidelines for the Management of Drug Phase I Clinical Trials (Draft)","year":"2011"},{"key":"10.1016\/j.clinsp.2026.101077_bib0017","series-title":"Abiraterone Acetate Tablets Label (Package Insert)","year":"2011"},{"key":"10.1016\/j.clinsp.2026.101077_bib0018","series-title":"Technical Guidelines for Human Bioequivalence Study of Chemical Generic Drugs with Pharmacokinetic Parameters as the End Point Evaluation Index","year":"2016"},{"key":"10.1016\/j.clinsp.2026.101077_bib0019","series-title":"Technical Guidelines for Research on Bioavailability and Bioequiva Lence of Chemical Drug Preparations in Humans","year":"2005"},{"issue":"9","key":"10.1016\/j.clinsp.2026.101077_bib0020","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cpdd.1097","article-title":"Pharmacokinetics and bioequivalence of 2 oral formulations of domperidone after single-dose administration in healthy Chinese subjects","volume":"11","author":"Ye","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"10.1016\/j.clinsp.2026.101077_bib0021","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00210-022-02337-w","article-title":"Pharmacokinetics and bioequivalence evaluation of 2 oral formulations of methotrexate tablets in healthy Chinese volunteers under fasting and fed conditions","volume":"396","author":"Zuo","year":"2023","journal-title":"Naunyn Schmiedeb Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101077_bib0022","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40360-024-00743-9","article-title":"Pharmacokinetics and bioequivalence evaluation of two oral formulations of cotrimoxazole tablets in healthy Chinese volunteers under fasting conditions","volume":"25","author":"Zuo","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.clinsp.2026.101077_bib0023","series-title":"Guidance For Industry: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA","year":"2021"},{"key":"10.1016\/j.clinsp.2026.101077_bib0024","series-title":"Common Terminology Criteria For Adverse Events (CTCAE) Version 5.0","year":"2017"},{"issue":"6","key":"10.1016\/j.clinsp.2026.101077_bib0025","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","article-title":"High-risk prostate cancer-classification and therapy","volume":"11","author":"Chang","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101077_bib0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semradonc.2016.08.002","article-title":"Prostate cancer genetics: variation by race, ethnicity, and geography","volume":"27","author":"Rebbeck","year":"2017","journal-title":"Semin Radiat Oncol"},{"issue":"40","key":"10.1016\/j.clinsp.2026.101077_bib0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7748\/ns.30.40.17.s20","article-title":"Prostate cancer","volume":"30","year":"2016","journal-title":"Nurs Stand"},{"issue":"22","key":"10.1016\/j.clinsp.2026.101077_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214257","article-title":"Complexities of prostate cancer","volume":"23","author":"Wasim","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.clinsp.2026.101077_bib0029","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/14656566.2021.1915287","article-title":"An up-to-date evaluation of abiraterone for the treatment of prostate cancer","volume":"22","author":"Shpilsky","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.clinsp.2026.101077_bib0030","first-page":"1363","article-title":"Cost-utility analysis of abiraterone in first-line treatment of metastatic castration-resistant prostate cancer","volume":"23","author":"Shen","year":"2023","journal-title":"Eval Anal Drug-Use Hosp China"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593226002048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593226002048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:21:36Z","timestamp":1793964096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593226002048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"alternative-id":["S1807593226002048"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2026.101077","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and bioequivalence evaluation of two abiraterone acetate tablets under fasting conditions in healthy Chinese volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2026.101077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101077"}}